Karyopharm Therapeutics (KPTI) Misses Q4 EPS by 571c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($5.71). Revenue for the quarter came in at $34.08 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• GameStop CEO Cohen buys 1.15M shares
• Vicor raises Q3 2026 revenue guidance on new licensing deal
• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar